Management of Imatinib-Resistant CML Patients

Publisher： Karger

E-ISSN： 2296-5262|30|11|574-580

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.11, 2007-10, pp. : 574-580

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML

By  

Acta Haematologica, Vol. 127, Iss. 3, 2012-01 ,pp. : 152-155

Karger

Access to resources Recommend Favorite

Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor

By  

Oncology, Vol. 90, Iss. 2, 2016-0 ,pp. : 112-117

Karger

Access to resources Recommend Favorite

Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature

By  

Cytogenetic and Genome Research, Vol. 150, Iss. 3-4, 2017-03 ,pp. : 273-280

Karger

Access to resources Recommend Favorite

Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 59-68

Karger

Access to resources Recommend Favorite

Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition

By                      

International Journal of Molecular Medicine, Vol. 31, Iss. 2, 2013-01 ,pp. : 453-458

Spandidos Publications

Access to resources Recommend Favorite